Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Myrbetriq

×

Overview

What is Myrbetriq?

Mirabegron is a beta-3 adrenergic agonist. The chemical name is 2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide having an empirical formula of CHNOS and a molecular weight of 396.51. The structural formula of mirabegron is:

Mirabegron is a white powder. It is practically insoluble in water (0.082 mg/mL). It is soluble in methanol and dimethyl sulfoxide.

Each MYRBETRIQ extended-release tablet, for oral administration contains either 25 mg or 50 mg of mirabegron and the following inactive ingredients: polyethylene oxide, polyethylene glycol, hydroxypropyl cellulose, butylated hydroxytoluene, magnesium stearate, hypromellose, yellow ferric oxide, and red ferric oxide (25 mg tablet only).



What does Myrbetriq look like?



What are the available doses of Myrbetriq?

Extended-release tablets:

3

What should I talk to my health care provider before I take Myrbetriq?

How should I use Myrbetriq?

MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

The recommended starting dose of MYRBETRIQ is 25 mg once daily with or without food. MYRBETRIQ 25 mg is effective within 8 weeks. Based on individual patient efficacy and tolerability the dose may be increased to 50 mg once daily .

MYRBETRIQ should be taken with water, swallowed whole and should not be chewed, divided, or crushed.


What interacts with Myrbetriq?

Sorry No Records found


What are the warnings of Myrbetriq?

Sorry No Records found


What are the precautions of Myrbetriq?

Sorry No Records found


What are the side effects of Myrbetriq?

Sorry No records found


What should I look out for while using Myrbetriq?

MYRBETRIQ is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet .


What might happen if I take too much Myrbetriq?

Mirabegron has been administered to healthy volunteers at single doses up to 400 mg. At this dose, adverse events reported included palpitations (1 of 6 subjects) and increased pulse rate exceeding 100 bpm (3 of 6 subjects). Multiple doses of mirabegron up to 300 mg daily for 10 days showed increases in pulse rate and systolic blood pressure when administered to healthy volunteers. Treatment for overdosage should be symptomatic and supportive. In the event of overdosage, pulse rate, blood pressure and ECG monitoring is recommended.


How should I store and handle Myrbetriq?

Store at MYRBETRIQ is supplied as oval, film coated extended-release tablets, available in bottles and blister units as follows:Strength                                   25 mg                               50 mgColor                                        brown                               yellowDebossed                                  logo, 325                  logo, 355Bottle of 30                              NDC 0469-2601-30          NDC 0469-2602-30Bottle of 90                              NDC 0469-2601-90          NDC 0469-2602-90Unit dose pack of 100              NDC 0469-2601-71          NDC 0469-2602-71Store at 25C (77F) with excursions permitted from 15C to 30C (59F to 86F) {see USP controlled Room Temperature}.MYRBETRIQ is supplied as oval, film coated extended-release tablets, available in bottles and blister units as follows:Strength                                   25 mg                               50 mgColor                                        brown                               yellowDebossed                                  logo, 325                  logo, 355Bottle of 30                              NDC 0469-2601-30          NDC 0469-2602-30Bottle of 90                              NDC 0469-2601-90          NDC 0469-2602-90Unit dose pack of 100              NDC 0469-2601-71          NDC 0469-2602-71Store at 25C (77F) with excursions permitted from 15C to 30C (59F to 86F) {see USP controlled Room Temperature}.MYRBETRIQ is supplied as oval, film coated extended-release tablets, available in bottles and blister units as follows:Strength                                   25 mg                               50 mgColor                                        brown                               yellowDebossed                                  logo, 325                  logo, 355Bottle of 30                              NDC 0469-2601-30          NDC 0469-2602-30Bottle of 90                              NDC 0469-2601-90          NDC 0469-2602-90Unit dose pack of 100              NDC 0469-2601-71          NDC 0469-2602-71Store at 25C (77F) with excursions permitted from 15C to 30C (59F to 86F) {see USP controlled Room Temperature}.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by laboratory experiments using the cloned human beta-3 AR. Mirabegron relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of beta-3 AR which increases bladder capacity. Although mirabegron showed very low intrinsic activity for cloned human beta-1 AR and beta-2 AR, results in humans indicate that beta-1 AR stimulation occurred at a mirabegron dose of 200 mg.

Non-Clinical Toxicology
MYRBETRIQ is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet .

MYRBETRIQ can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. MYRBETRIQ is not recommended for use in patients with severe uncontrolled hypertension (defined as systolic blood pressure greater than or equal to 180 mm Hg and/or diastolic blood pressure greater than or equal to 110 mm Hg)

In two, randomized, placebo-controlled, healthy volunteer studies, MYRBETRIQ was associated with dose-related increases in supine blood pressure. In these studies, at the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg greater than placebo.

In contrast, in OAB patients in clinical trials, the mean increase in systolic and diastolic blood pressure at the maximum recommended dose of 50 mg was approximately 0.5 - 1 mm Hg greater than placebo. Worsening of pre-existing hypertension was reported infrequently in MYRBETRIQ patients.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).